Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25698327 | 0.90 | GBA1 (0.50) | GBA1DDB1CRBNHDAC8POLB | |
| SCHEMBL11730331 | 0.85 | GBA1 (0.61) | GBA1DDB1CRBNCCR3GRIN2B | |
| SCHEMBL9377950 | 0.83 | GBA1 (0.42) | GBA1 | |
| SCHEMBL22201217 | 0.82 | GBA1 (0.47) | GBA1DDB1CRBNHDAC8CYP19A1 | |
| SCHEMBL1269308 | 0.82 | GBA1 (0.47) | GBA1DDB1CRBNHDAC8CYP19A1 | |
| SCHEMBL7448110 | 0.81 | GBA1 (0.59) | GBA1POLBCCR3CYP19A1GRIN2B | |
| SCHEMBL27547225 | 0.81 | GBA1 (0.59) | GBA1POLBCCR3CYP19A1GRIN2B | |
| SCHEMBL8399347 | 0.80 | GBA1 (0.54) | GBA1DDB1CRBNPOLB | |
| Hydrochloric Acid SCHEMBL8329261 | 0.79 | GBA1 (0.58) | GBA1POLBCCR3CYP19A1GRIN2B | |
| SCHEMBL11359163 | 0.78 | HDAC8 (0.50) | GBA1DDB1CRBNHDAC8CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925357-B | Acylhydrazone compound, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2023-06-06 | — | — | CN | disclosed |
| CN-109384803-B | ATX inhibitor and preparation method and application thereof | 广州市恒诺康医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-111925357-A | Acylhydrazone compound, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2020-11-13 | — | — | CN | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| CN-101448844-B | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2000039114-A2 | SUBSTITUTED OXIMES AND HYDRAZONES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999021539-A1 | METHOD FOR TREATING DISEASE-RELATED OR DRUG-INDUCED DYSKINESIAS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5629322-A | TREATMENT OF NEURODEGENERATIVE DISORDERS, DISORDERS OF GASTROINTESTINAL MOTILITY AND INFLAMMATION | MERCK & CO., INC. (US) | 1997-05-13 | — | — | US | disclosed |
| US-4977166-A | ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | RHONE-POULENC SANTE (FR) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | GBA1 1143/4885DDB1 1902/4885CRBN 1668/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | GBA1 1143/4885DDB1 1902/4885CRBN 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.